Vascular Regeneration for Ischemic Retinopathies: Hope from Cell Therapies

ABSTRACT

Retinal vascular diseases, such as diabetic retinopathy, retinopathy of prematurity, retinal vein occlusion, ocular ischemic syndrome and ischemic optic neuropathy, are leading causes of vision impairment and blindness. Whilst drug, laser or surgery-based treatments for the late stage complications of many of these diseases are available, interventions that target the early vasodegenerative stages are lacking. Progressive vasculopathy and ensuing ischemia is an underpinning pathology in many of these diseases, leading to hypoperfusion, hypoxia, and ultimately pathological neovascularization and/or edema in the retina and other ocular tissues, such as the optic nerve and iris. Therefore, repairing the retinal vasculature may prevent progression of ischemic retinopathies into late stage vascular complications. Various cell types have been explored for their vascular repair potential. Endothelial progenitor cells, mesenchymal stem cells and induced pluripotent stem cells are studied for their potential to integrate with the damaged retinal vasculature and limit ischemic injury. Clinical trials for some of these cell types have confirmed safety and feasibility in the treatment of ischemic diseases, including some retinopathies. Another promising avenue is mobilization of endogenous endothelial progenitors, whereby reparative cells are moved from their niche to circulating blood to target and home into ischemic tissues. Several aspects and properties of these cell types have yet to be elucidated. Nevertheless, we foresee that cell therapy, whether through delivery of exogenous or enhancement of endogenous reparative cells, will become a valuable and beneficial treatment for ischemic retinopathies.

KEYWORDS:

• Retina
• retinal ischemia
• cell therapy
• endothelial progenitors
• mesenchymal stem cells
• induced pluripotent stem cells

Disclosure statement

Authors declare no potential conflict of interest.

Additional information

Funding

RM is funded by the JDRF [5-CDA-2014-225-A-N], the National Eye Research Centre SAC016, The Belfast Association for the Blind and the MRC. AS is funded by Fight for Sight, an SFI-DfE (NI) Investigator Award, The Jules Thorn Trust and the Health & Social Care R&D Division, Northern Ireland [STL/4748/13].